Cell therapy is one of those fields where the science keeps outrunning the manufacturing. Researchers can now reprogram stem cells to treat Parkinson's, repair heart tissue, and fight cancer in ways that seemed like science fiction a decade ago. The problem isn't the biology anymore. It's the recipes. Specifically, the proteins that tell cells how to grow, differentiate, and behave in the lab.

Stockholm-based BioLamina makes those proteins, laminins, which are the extracellular matrix that surrounds every cell in your body. And the European Investment Bank just committed EUR 20 million in venture debt to help the company scale production. That's the EIB's largest venture debt deal with a Swedish biotech to date, and it signals something bigger: Europe's public financing institutions are starting to treat cell therapy infrastructure as critical industrial capacity.

Laminins aren't glamorous. They're not a drug or a device. They're a family of large glycoproteins, at least 16 types in mammals, that form the scaffolding cells need to attach, grow, and specialize correctly. Without the right laminin combination, stem cells drift. They differentiate unpredictably. Experiments fail. Therapies produce inconsistent results.

BioLamina was founded in 2009 by father and son Dr. Karl Tryggvason and Kristian Tryggvason. Karl, a professor at the Karolinska Institute, spent decades mapping how different laminin isoforms interact with different cell types. That research became BioLamina's product line: cell-specific culture substrates that give researchers reproducible, reliable results.

Think of it this way. If cell therapy is cooking, laminins are the pans. You can have the best ingredients in the world, but if the pan sticks, burns, or distributes heat unevenly, the dish fails. BioLamina makes the pan that works every time.

The EIB financing is structured as venture debt, not equity. That's a deliberate choice. Venture debt lets BioLamina scale manufacturing without diluting existing shareholders. It extends the company's runway and provides growth capital while preserving the cap table for a future equity round at a higher valuation.

For the EIB, it's also strategic. Vice-President Karl Nehammer framed the deal explicitly: 'Europe needs to turn scientific excellence into global companies.' The subtext is clear. Cell therapy manufacturing is concentrating in the US and Asia. If Europe wants to retain its biotech companies, it needs to fund the infrastructure that keeps them from relocating.

Making laminins at research scale is one thing. Making them at the volumes needed for commercial cell therapies is something else entirely. These are complex recombinant proteins produced in mammalian cell culture systems. Scaling means bigger bioreactors, more stringent quality control, and regulatory compliance across multiple jurisdictions.

The EUR 20 million goes directly toward this challenge. BioLamina needs to expand production capacity to meet growing demand from pharma companies, cell therapy developers, and academic research institutions. As more cell therapies move from clinical trials to approved treatments, the demand for reliable, GMP-grade culture substrates will only accelerate.

There's something appealing about BioLamina's origin story. A university professor maps the biology. His son turns it into a business. Together they build a company that's now being backed by Europe's largest public investment institution. It's not the typical VC-funded blitz-scaling narrative. It's patient, scientifically-grounded company building that took 17 years to reach this inflection point.

The cell therapy market is projected to exceed $50 billion by 2030. Every therapy in that market needs culture substrates. Every substrate works better with the right laminin. BioLamina doesn't need to win every customer to build a significant business. It just needs to be the supplier that works when the stakes are highest, when the cells are going into a patient, not a petri dish. That's the position EUR 20 million is designed to secure.